Breaking News Instant updates and real-time market news.

2020-11-24 07:01:11 BMY Bristol-Myers $61.92 / +0.295 (+0.48%) 07:01 11/24/20 11/24 07:01 11/24/20 07:01	Bristol-Myers announces approval of Opdivo in Europe Bristol Myers Squibb announced that the European Commission, or EC, has approved Opdivo, or nivolumab, for the treatment of adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma, or ESCC, after prior fluoropyrimidine- and platinum-based combination chemotherapy. The EC's decision is based on results from the Phase 3 ATTRACTION-3 trial, a study sponsored by Ono Pharmaceutical of Japan, which demonstrated a statistically significant and clinically meaningful improvement in overall survival, or OS, in patients who received Opdivo versus chemotherapy. The safety profile for Opdivo was favorable compared with chemotherapy and consistent with previously reported studies of Opdivo in other solid tumors. In addition to this approval in the EU, Opdivo has been approved in five countries, including the U.S. and Japan, for the second-line treatment of patients with unresectable advanced, recurrent or metastatic ESCC.	15 Dec 20 Feb 27 Mar
BMY Bristol-Myers $61.92 / +0.295 (+0.48%) 11/23/20 BofA BofA upgrades Schrodinger to Buy after 'major' collaboration announcement 11/17/20 Mizuho Bristol-Myers Squibb CVR price target lowered to $3.34 from $6.17 at Mizuho 11/16/20 Societe Generale Bristol-Myers upgraded to Buy from Hold at Societe Generale 11/10/20 Bernstein Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein

2020-11-24 07:01:11

BMY

Bristol-Myers

$61.92 / +0.295 (+0.48%)

07:01

11/24/20

11/24

07:01

11/24/20

07:01

Bristol-Myers announces approval of Opdivo in Europe

Bristol Myers Squibb announced that the European Commission, or EC, has approved Opdivo, or nivolumab, for the treatment of adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma, or ESCC, after prior fluoropyrimidine- and platinum-based combination chemotherapy. The EC's decision is based on results from the Phase 3 ATTRACTION-3 trial, a study sponsored by Ono Pharmaceutical of Japan, which demonstrated a statistically significant and clinically meaningful improvement in overall survival, or OS, in patients who received Opdivo versus chemotherapy. The safety profile for Opdivo was favorable compared with chemotherapy and consistent with previously reported studies of Opdivo in other solid tumors. In addition to this approval in the EU, Opdivo has been approved in five countries, including the U.S. and Japan, for the second-line treatment of patients with unresectable advanced, recurrent or metastatic ESCC.

15
Dec
20
Feb
27
Mar

BMY Bristol-Myers

$61.92 / +0.295 (+0.48%)

11/23/20 BofA: BofA upgrades Schrodinger to Buy after 'major' collaboration announcement

11/17/20 Mizuho: Bristol-Myers Squibb CVR price target lowered to $3.34 from $6.17 at Mizuho

11/16/20 Societe Generale: Bristol-Myers upgraded to Buy from Hold at Societe Generale

11/10/20 Bernstein: Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein

TODAY'S FREE FLY STORIES

Hot Stocks	Velodyne Lidar Trunk.Tech Announce strategic partnership for autonomous trucking » 07:14 01/19/21 01/19 07:14 01/19/21 07:14 VLDR Velodyne Lidar $22.95 / -1.16 (-4.81%) Velodyne Lidar announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options VLDR Velodyne Lidar $22.95 / -1.16 (-4.81%) 01/14/21 Velodyne encourages government, industry collaboration to advance vehicle safety 01/07/21 Velodyne Lidar withdraws any previous FY21 guidance 12/18/20 Velodyne Lidar signs sales agreement with Motional for Alpha Prime sensors 12/16/20 Velodyne Lidar selected by May Mobility for Alpha Prime sensors VLDR Velodyne Lidar $22.95 / -1.16 (-4.81%) 01/14/21 Fly Intel: Top five analyst initiations 01/14/21 Benchmark Benchmark starts 'first mover' Velodyne Lidar at Buy with $32 price target 01/14/21 Benchmark Velodyne Lidar initiated with a Buy at Benchmark 01/08/21 Craig-Hallum Craig-Hallum a buyer of Velodyne after 'frustrating' preannouncement VLDR Velodyne Lidar $22.95 / -1.16 (-4.81%) 01/07/21 Velodyne Lidar sees Q4 revenue $15.5M-$16M, consensus $29.55M VLDR Velodyne Lidar $22.95 / -1.16 (-4.81%) 12/15/20 Mobileye CEO sees building own LIDAR sensors to control costs, Reuters says 12/08/20 Citron pans 'suckers game' Luminar, prefers Velodyne Lidar shares 12/08/20 Velodyne Lidar shares will rally to $30, Citron Research says VLDR Velodyne Lidar $22.95 / -1.16 (-4.81%) 01/08/21 Fly Intel: Pre-market Movers 12/15/20 Luminar under pressure as Mobileye CEO shares in-house LIDAR plans 12/08/20 Luminar slips as Northland cuts rating, Citron sees shares back to $20 10/05/20 Fly Intel: After-Hours Movers VLDR Velodyne Lidar $22.95 / -1.16 (-4.81%) 12/30/20 Velodyne Lidar call volume above normal and directionally bullish 12/24/20 Largest borrow rate increases among liquid names 12/22/20 Unusually active option classes on open December 22nd 12/21/20 Velodyne Lidar call volume above normal and directionally bullish
Upgrade	Evercore ISI upgrades 'COVID recovery idea' WWE to Outperform » 07:14 01/19/21 01/19 07:14 01/19/21 07:14 WWE WWE $50.86 / -0.89 (-1.72%) Evercore ISI analyst John… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events WWE WWE $50.86 / -0.89 (-1.72%) 11/25/20 WWE names Karen Mullane as Controller & Chief Accounting Officer 11/20/20 WWE, Credit One Bank enter multi-year partnership 09/22/20 WWE director sells 57.6K shares of common stock 09/21/20 iQIYI announces partnership with WWE WWE WWE $50.86 / -0.89 (-1.72%) 06:21 Today Evercore ISI WWE upgraded to Outperform from In Line at Evercore ISI 01/11/21 Fly Intel: Top five analyst initiations 01/11/21 Barclays WWE initiated with an Equal Weight at Barclays 10/27/20 Morgan Stanley WWE price target lowered to $47 from $52 at Morgan Stanley WWE WWE $50.86 / -0.89 (-1.72%) 10/29/20 WWE reports Q3 adjusted EPS 56c, consensus 38c 07/30/20 WWE reports Q2 adjusted EPS 45c, consensus 14c 25 Mar WWE WWE $50.86 / -0.89 (-1.72%) 11/20/20 WWE agrees to multi-year partnership deal with Credit One, Sportico reports WWE WWE $50.86 / -0.89 (-1.72%) 07/30/20 Fly Intel: After-Hours Movers 02/04/21 WWE - WWE
Hot Stocks	Iceland Foods extends distribution partnership with XPO Logistics » 07:13 01/19/21 01/19 07:13 01/19/21 07:13 XPO XPO Logistics $118.85 / -1.915 (-1.59%) XPO Logistics has renewed… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options XPO XPO Logistics $118.85 / -1.915 (-1.59%) 01/14/21 XPO Logistics surpasses 300,000 app downloads for Drive XPO app 01/12/21 XPO Logistics announces senior leadership for logistics spin-off 01/11/21 XPO Logistics partners with Truckers Against Trafficking 01/05/21 XPO Logistics announces pilot of BR training for LTL employees XPO XPO Logistics $118.85 / -1.915 (-1.59%) 06:09 Today UBS XPO Logistics initiated with a Buy at UBS 01/12/21 JPMorgan XPO Logistics price target raised to $135 from $122 at JPMorgan 01/08/21 Barclays XPO Logistics price target raised to $136 from $100 at Barclays 12/07/20 Credit Suisse XPO Logistics price target raised to $140 from $114 at Credit Suisse XPO XPO Logistics $118.85 / -1.915 (-1.59%) 11/05/20 Notable companies reporting after market close 11/05/20 XPO Logistics sees 2020 adjusted EBITDA $1.35B 11/05/20 XPO Logistics sees Q4 adjusted EBITDA $400M-$410M 11/05/20 XPO Logistics reports Q3 adjusted EPS 84c, consensus 40c XPO XPO Logistics $118.85 / -1.915 (-1.59%) 11/23/20 Blackstone drops out of bidding for XPO European unit, Bloomberg reports 11/23/20 XPO Logistics also weighing spinoff of European unit, Bloomberg says 11/23/20 XPO European unit sale slows as Blackstone drops out, Bloomberg reports 11/10/20 Amazon moving into middle-mile trucking business, The Information reports XPO XPO Logistics $118.85 / -1.915 (-1.59%) 07/30/20 Fly Intel: After-Hours Movers XPO XPO Logistics $118.85 / -1.915 (-1.59%) 08/14/20 Unusually active option classes on open August 14th
Hot Stocks	Seres Therapeutics to present new SER-109 data at Keystone Symposium » 07:13 01/19/21 01/19 07:13 01/19/21 07:13 MCRB Seres Therapeutics $24.47 / -2.26 (-8.45%) Seres Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options MCRB Seres Therapeutics $24.47 / -2.26 (-8.45%) 01/06/21 Seres Therapeutics publishes data from Phase 1b trial of SER-287 for UC 11/06/20 Seres Therapeutics doses first patient in SER-301 trial 10/22/20 Seres Therapeutics appoints David Ege as CTO, Jayne Gansler as CPO 09/11/20 Seres Therapeutics announces FDA correspondence regarding SER-109 BLA MCRB Seres Therapeutics $24.47 / -2.26 (-8.45%) 01/12/21 Piper Sandler Additional Seres '109 analysis strengthens BLA filing, says Piper Sandler 12/23/20 JMP Securities Seres Therapeutics initiated with a Market Perform at JMP Securities 11/09/20 Oppenheimer Seres Therapeutics price target raised to $38 from $34 at Oppenheimer 11/09/20 Piper Sandler Seres Therapeutics price target raised to $49 from $40 at Piper Sandler MCRB Seres Therapeutics $24.47 / -2.26 (-8.45%) 11/09/20 Seres Therapeutics reports Q3 EPS ,(36c) consensus (25c) 07/28/20 Seres Therapeutics reports Q2 EPS (28c), consensus (26c) 13 Aug MCRB Seres Therapeutics $24.47 / -2.26 (-8.45%) 08/18/20 Fly Intel: Pre-market Movers 08/10/20 Fly Intel: Pre-market Movers MCRB Seres Therapeutics $24.47 / -2.26 (-8.45%) 08/19/20 Largest borrow rate increases among liquid names 08/10/20 Seres Therapeutics put volume heavy and directionally bearish
Hot Stocks	CytoSorb approved in Korea for all EU approved indications » 07:13 01/19/21 01/19 07:13 01/19/21 07:13 CTSO CytoSorbents $8.58 / -0.21 (-2.39%) , FMS Fresenius Medical $41.61 / -0.14 (-0.34%) CytoSorbents (CTSO)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals CTSO CTSO CytoSorbents $8.58 / -0.21 (-2.39%) 01/12/21 Health Canada authorizes CytoSorb for use in hospitalized COVID-19 patients 01/04/21 CytoSorbents gets Medical Device Authorization for CytoSorb in COVID-19 patients 12/09/20 CytoSorbents announces publication of CytoSorb matched analysis 11/04/20 CytoSorbents sees Q4 as 'one of the company's strongest' in product sales CTSO FMS CTSO CytoSorbents $8.58 / -0.21 (-2.39%) 01/04/21 B. Riley Securities CytoSorbents price target raised to $17 from $16 at B. Riley Securities 09/01/20 SVB Leerink CytoSorbents initiated with an Outperform at SVB Leerink 08/25/20 B. Riley FBR CytoSorbents 29% pullback from highs a buying opportunity, says B. Riley FBR 06/02/20 B. Riley FBR CytoSorbents gaining relevance as COVID-19 treatment, says B. Riley FBR FMS Fresenius Medical $41.61 / -0.14 (-0.34%) 01/11/21 Jefferies Fresenius Medical downgraded to Underperform from Hold at Jefferies 12/09/20 Morgan Stanley Fresenius Medical price target raised to EUR 75 from EUR 74 at Morgan Stanley 11/10/20 Deutsche Bank Fresenius Medical price target lowered to EUR 87 from EUR 97 at Deutsche Bank 11/05/20 UBS Fresenius Medical price target lowered to EUR 94 from EUR 95 at UBS CTSO CTSO CytoSorbents $8.58 / -0.21 (-2.39%) 11/04/20 CytoSorbents reports Q3 EPS (2c), consensus (9c) 08/04/20 CytoSorbents reports Q2 EPS (8c), consensus (8c) 07/20/20 CytoSorbents sees Q2 revenue approximately $9.8M, consensus $9.25M 22 Jul FMS FMS Fresenius Medical $41.61 / -0.14 (-0.34%) 12/30/20 Fresenius to administer Lilly, Regeneron COVID antibody drugs, Reuters says

Hot Stocks	Miragen Therapeutics appoints Jonathan Violin as CEO, Barrett Katz as CMO » 07:12 01/19/21 01/19 07:12 01/19/21 07:12 MGEN Miragen Therapeutics $23.29 / -1.8 (-7.17%) , VRDN Viridian Therapeutics $0.00 / + (+0.00%) , BBIO BridgeBio $68.61 / -1.19 (-1.70%) The Company announced the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events MGEN VRDN BBIO MGEN Miragen Therapeutics $23.29 / -1.8 (-7.17%) 07:10 Today Miragen Therapeutics changes name to Viridian Therapeutics 07:07 Today Avrobio appoints Diana Escolar as CMO 12/17/20 Miragen Therapeutics enters license agreement with Xencor for Xtend technology 10/29/20 Point72 reports 9.5% passive stake in Miragen Therapeutics VRDN Viridian Therapeutics $0.00 / + (+0.00%) 07:10 Today Miragen Therapeutics changes name to Viridian Therapeutics BBIO BridgeBio $68.61 / -1.19 (-1.70%) 01/04/21 ISS recommends BridgeBio, Eidos shareholders vote for proposed merger 12/23/20 BridgeBio, UCSF collaborate for development of therapies for genetic diseases 12/11/20 Eidos jumps after filing shows rival takeover interest over $120 per share 12/07/20 BridgeBio, Maze Therapeutics establish JV to advance precision medicine MGEN VRDN BBIO MGEN Miragen Therapeutics $23.29 / -1.8 (-7.17%) 12/31/20 Oppenheimer Miragen Therapeutics price target raised to $37 from $5 at Oppenheimer 12/15/20 JMP Securities Miragen Therapeutics initiated with an Outperform at JMP Securities 11/24/20 Wedbush Miragen Therapeutics assumed with Outperform rating at Wedbush 10/06/20 Fly Intel: Top five analyst downgrades VRDN Viridian Therapeutics $0.00 / + (+0.00%) BBIO BridgeBio $68.61 / -1.19 (-1.70%) 01/11/21 H.C. Wainwright BridgeBio price target raised to $87 from $64 at H.C. Wainwright 12/30/20 Citi Eidos Therapeutics price target raised to $129 from $73.26 at Citi 12/14/20 BTIG BridgeBio price target raised to $91 from $49 at BTIG 12/10/20 H.C. Wainwright BridgeBio price target raised to $64 from $53 at H.C. Wainwright MGEN BBIO MGEN Miragen Therapeutics $23.29 / -1.8 (-7.17%) 11/10/20 Miragen sees sufficient capital to fund through the end of 2023 11/10/20 Miragen Therapeutics reports Q3 EPS (10c), consensus (13c) 08/05/20 Miragen Therapeutics reports Q2 EPS (12c), consensus (16c) BBIO BridgeBio $68.61 / -1.19 (-1.70%) 11/05/20 BridgeBio reports Q3 EPS (98c), consensus (92c) 08/11/20 BridgeBio reports Q2 EPS ($1.03), consensus (77c) 29 May BBIO BBIO BridgeBio $68.61 / -1.19 (-1.70%) 12/11/20 GlaxoSmithKline offered $120 per share for Eidos Therapeutics, Bloomberg says MGEN MGEN Miragen Therapeutics $23.29 / -1.8 (-7.17%) 10/29/20 Fly Intel: After-Hours Movers 10/05/20 Fly Intel: After-Hours Movers 13:00 Today BridgeBio Pharma, Inc.
Hot Stocks	Taysha gets both rare pediatric disease and orphan drug designations for TSHA-10 » 07:12 01/19/21 01/19 07:12 01/19/21 07:12 TSHA Taysha Gene Therapies $29.86 / +1.21 (+4.22%) Taysha Gene Therapies… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate TSHA Taysha Gene Therapies $29.86 / +1.21 (+4.22%) 01/04/21 Taysha Gene Therapies announces multi-year collaboration with AllStripes 12/21/20 Taysha announces that Ontario hospital received CTA approval from Health Canada 12/03/20 Taysha gets rare pediatric and orphan drug designations for TSHA-103 11/05/20 Taysha Gene Therapies, Catalent announce partnership to develop gene therapies TSHA Taysha Gene Therapies $29.86 / +1.21 (+4.22%) 01/04/21 Oppenheimer Taysha Gene Therapies initiated with an Outperform at Oppenheimer 10/19/20 Chardan Taysha Gene Therapies initiated with a Buy at Chardan 10/19/20 Jefferies Taysha Gene Therapies initiated with a Buy at Jefferies 10/19/20 Morgan Stanley Taysha Gene Therapies initiated with an Overweight at Morgan Stanley 24 Sep
Initiation	Xpeng initiated with a Hold at Jefferies » 07:11 01/19/21 01/19 07:11 01/19/21 07:11 XPEV Xpeng $47.83 / -2.51 (-4.99%) Jefferies analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options XPEV Xpeng $47.83 / -2.51 (-4.99%) 01/15/21 Xpeng unveils beta version of Navigation Guided Pilot autonomous driving system 01/11/21 Telenav to provide connected navigation for Xpeng customers in Europe 01/03/21 Xpeng announces vehicle delivery results for December 2020 01/03/21 Xpeng partners with lidar maker Livox XPEV Xpeng $47.83 / -2.51 (-4.99%) 01/04/21 Citi Xpeng partnership with Livox is 'very positive,' says Citi 12/21/20 Wedbush Tesla price target raised to $715 from $560 at Wedbush 12/14/20 Fly Intel: Top five analyst initiations 12/14/20 Daiwa Xpeng initiated with a Sell at Daiwa XPEV Xpeng $47.83 / -2.51 (-4.99%) 11/12/20 Xpeng sees Q4 revenue RMB 2.2B, up 244% year-over-year 11/12/20 Xpeng reports Q3 EPS (32c), deliveries of 8,578 09 Dec 27 Aug XPEV Xpeng $47.83 / -2.51 (-4.99%) 12/12/20 Nio, Xeng, Li Auto not the next Tesla, Barron's says 12/02/20 House approves bill restricting Chinese firms on U.S exchanges, Bloomberg says 12/01/20 Lucid Motors finishes 1st part of construction on Arizona factory, Electrek says XPEV Xpeng $47.83 / -2.51 (-4.99%) 12/21/20 Tesla under pressure on first trading day on S&P 500 Index 11/30/20 Nikola plunges after new GM agreement includes no stake 11/12/20 Fly Intel: Pre-market Movers 10/14/20 NIO jumps as analysts say buy on 'meaningful' upside, backlog increase XPEV Xpeng $47.83 / -2.51 (-4.99%) 01/12/21 XPeng call volume above normal and directionally bullish 12/31/20 XPeng call volume above normal and directionally bullish 12/29/20 XPeng call volume above normal and directionally bullish 12/15/20 XPeng call volume above normal and directionally bullish
Hot Stocks	Applied DNA Sciences announces Linea COVID-19 Assay Kit identifies variants » 07:11 01/19/21 01/19 07:11 01/19/21 07:11 APDN Applied DNA Sciences $10.94 / +2.06 (+23.20%) Applied DNA Sciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events APDN Applied DNA Sciences $10.94 / +2.06 (+23.20%) 01/15/21 Applied DNA Sciences provides update on COVID-19 diagnostics, testing 01/08/21 Applied DNA up 28% after noting inclusion on FDA list for COVID mutation tests 01/08/21 Applied DNA says FDA lists Linea test as able to detect COVID S-gene mutation 12/29/20 Applied DNA Sciences, CLEARED4 enter reseller, sales referral partnership APDN Applied DNA Sciences $10.94 / +2.06 (+23.20%) 01/14/21 H.C. Wainwright Applied DNA Sciences price target lowered to $14 from $18 at H.C. Wainwright 01/11/21 H.C. Wainwright Applied DNA Sciences price target raised to $18 from $12 at H.C. Wainwright 12/30/20 H.C. Wainwright H.C. Wainwright keeps $12 target on Applied DNA Sciences after partnership 12/18/20 H.C. Wainwright Applied DNA Sciences price target lowered to $12 from $20 at H.C. Wainwright APDN Applied DNA Sciences $10.94 / +2.06 (+23.20%) 01/04/21 Applied DNA Sciences sees Q1 revenue $1.3M-$1.6M, two estimates $1.05M 03/15/21 33rd Annual Roth Virtual Conference
Hot Stocks	Miragen Therapeutics changes name to Viridian Therapeutics » 07:10 01/19/21 01/19 07:10 01/19/21 07:10 MGEN Miragen Therapeutics $23.29 / -1.8 (-7.17%) , VRDN Viridian Therapeutics $0.00 / + (+0.00%) miRagen Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly MGEN MGEN Miragen Therapeutics $23.29 / -1.8 (-7.17%) 07:07 Today Avrobio appoints Diana Escolar as CMO 12/17/20 Miragen Therapeutics enters license agreement with Xencor for Xtend technology 10/29/20 Point72 reports 9.5% passive stake in Miragen Therapeutics 10/28/20 Miragen Therapeutics acquires Viridian Therapeutics in stock-for-stock deal MGEN VRDN MGEN Miragen Therapeutics $23.29 / -1.8 (-7.17%) 12/31/20 Oppenheimer Miragen Therapeutics price target raised to $37 from $5 at Oppenheimer 12/15/20 JMP Securities Miragen Therapeutics initiated with an Outperform at JMP Securities 11/24/20 Wedbush Miragen Therapeutics assumed with Outperform rating at Wedbush 10/06/20 Fly Intel: Top five analyst downgrades VRDN Viridian Therapeutics $0.00 / + (+0.00%) MGEN MGEN Miragen Therapeutics $23.29 / -1.8 (-7.17%) 11/10/20 Miragen sees sufficient capital to fund through the end of 2023 11/10/20 Miragen Therapeutics reports Q3 EPS (10c), consensus (13c) 08/05/20 Miragen Therapeutics reports Q2 EPS (12c), consensus (16c) MGEN MGEN Miragen Therapeutics $23.29 / -1.8 (-7.17%) 10/29/20 Fly Intel: After-Hours Movers 10/05/20 Fly Intel: After-Hours Movers

Hot Stocks	Nevro announces data supporting use of HF10 therapy » 07:09 01/19/21 01/19 07:09 01/19/21 07:09 NVRO Nevro $175.11 / -0.555 (-0.32%) Nevro announced the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals Events NVRO Nevro $175.11 / -0.555 (-0.32%) 12/28/20 Nevro announces FDA submission for HF10 in PDN patients 12/14/20 Boston Scientific says stipulation of dismissal filed in Nevro patent case 12/14/20 Nevro to conclude its Boston Scientific lawsuit in DC area 11/11/20 Nevro continues to target flat annual growth in Q4 NVRO Nevro $175.11 / -0.555 (-0.32%) 01/06/21 Truist Nevro price target raised to $205 from $175 at Truist 01/05/21 Baird Nevro price target raised to $200 from $180 at Baird 01/04/21 Wells Fargo Nevro price target raised to $215 from $177 at Wells Fargo 12/31/20 Guggenheim Nevro price target raised to $205 from $190 at Guggenheim NVRO Nevro $175.11 / -0.555 (-0.32%) 01/11/21 Nevro sees FY20 revenue $362M, consensus $358.76M 01/11/21 Nevro sees Q4 revenue $109.7M, consensus $106.54M 11/05/20 Nevro reports Q3 EPS (29c), consensus (59c) 08/05/20 Nevro reports Q2 EPS ($1.21), consensus ($1.62) 02 Apr NVRO Nevro $175.11 / -0.555 (-0.32%) 01/07/21 Nevro named a short idea, accused of fraud by Scorpion Capital 02/24/21 Nevro - NVRO
Recommendations	Peck price target raised to $22 from $9.50 at Alliance Global Partners » 07:09 01/19/21 01/19 07:09 01/19/21 07:09 PECK Peck $16.13 / -2.7 (-14.34%) Alliance Global Partners… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research PECK Peck $16.13 / -2.7 (-14.34%) 01/05/21 Peck to acquire iSun Energy in all-stock transaction, change name 11/12/20 Sunworks terminates merger agreement with The Peck Company 10/13/20 Peck awarded $7.64M in contracts for projects in Vermont 10/07/20 Peck gets $7.256M EPC contract for Rhode Island solar project PECK Peck $16.13 / -2.7 (-14.34%) 12/21/20 Alliance Global Partners Peck initiated with a Buy at Alliance Global Partners
Recommendations	Cloudflare price target raised to $85 from $70 at RBC Capital » 07:09 01/19/21 01/19 07:09 01/19/21 07:09 NET Cloudflare $77.86 / -2.595 (-3.23%) RBC Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options NET Cloudflare $77.86 / -2.595 (-3.23%) 10/12/20 Cloudflare spikes higher after announcing Cloudflare One NET Cloudflare $77.86 / -2.595 (-3.23%) 12/15/20 BTIG BTIG raises price targets on select security and software applications names 12/09/20 JPMorgan Cloudflare downgraded to Neutral from Overweight at JPMorgan 12/01/20 Fly Intel: Top five analyst initiations 12/01/20 KeyBanc Cloudflare initiated with an Overweight at KeyBanc NET Cloudflare $77.86 / -2.595 (-3.23%) 11/05/20 Cloudflare raises FY20 adj. EPS view to (13c)-(12c) from (18c)-(17c) 11/05/20 Cloudflare sees Q4 adjusted EPS (4c)-(3c), consensus (5c) 11/05/20 Cloudflare reports Q3 adjusted EPS (2c), consensus (5c) 11/05/20 Notable companies reporting after market close NET Cloudflare $77.86 / -2.595 (-3.23%) 12/08/20 Cloudflare, Fastly working with Apple to create Oblivious DNS, AppleInsider says 09/01/20 Hackers test security of Trump campaign sites ahead of election, Reuters says NET Cloudflare $77.86 / -2.595 (-3.23%) 12/09/20 JPMorgan downgrades Zoom, upgrades Autodesk in software ratings shakeup 11/06/20 Fly Intel: Pre-market Movers 11/05/20 Fly Intel: After-Hours Movers 10/15/20 Fastly tumbles as analysts cut rating after TikTok-related sales hit 02/11/21 Cloudflare - NET 02/12/21 Cloudflare, Inc. NET Cloudflare $77.86 / -2.595 (-3.23%) 01/08/21 Cloudflare call volume above normal and directionally bullish 12/24/20 Cloudflare call volume above normal and directionally bullish 12/18/20 Cloudflare call volume above normal and directionally bullish 12/14/20 Cloudflare call volume above normal and directionally bullish
Hot Stocks	LabCorp appoints Dr. Deborah Ann Sesok-Pizzini as Chief Medical Officer » 07:08 01/19/21 01/19 07:08 01/19/21 07:08 LH LabCorp $223.54 / +3.38 (+1.54%) Labcorp announced today… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 8 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options LH LabCorp $223.54 / +3.38 (+1.54%) 01/07/21 LabCorp awarded CDC contract to study COVID-19 variants 12/21/20 Walgreens Boots Alliance, LabCorp: Pixel by Labcorp COVID-19 kit now available 12/09/20 LabCorp receives FDA authorization for make at-home COVID-19 collection kits 12/01/20 Roche announces EUA for Elecsys Anti-SARS-CoV-2 S test LH LabCorp $223.54 / +3.38 (+1.54%) 01/14/21 Mizuho LabCorp price target raised to $242 from $234 at Mizuho 01/11/21 Fly Intel: Top five analyst upgrades 01/11/21 Argus LabCorp upgraded to Buy from Hold at Argus 01/11/21 Argus LabCorp upgraded to Buy from Hold at Argus LH LabCorp $223.54 / +3.38 (+1.54%) 10/27/20 LabCorp continues to not provide 2020 guidance 10/27/20 LabCorp reports Q3 adjusted EPS $8.41, consensus $5.25 07/28/20 LabCorp says FY20 guidance to remain withdrawn 07/28/20 LabCorp reports Q2 adjusted EPS $2.57, consensus 99c LH LabCorp $223.54 / +3.38 (+1.54%) 01/12/21 LabCorp CEO: COVID vaccine recipients don't need antibody test after, CNBC says 10/10/20 LabCorp 'now on a roll' after being tested by COVID, Barron's says 07/22/20 LabCorp: COVID spreading faster than it can add testing capacity, CNBC reports 07/21/20 Quest exec: 'No way' COVID testing capacity can cope with flu season, FT reports LH LabCorp $223.54 / +3.38 (+1.54%) 08/27/20 Abbott Labs jumps after securing FDA approval for $5 COVID-19 test 02/11/21 LabCorp - LH LH LabCorp $223.54 / +3.38 (+1.54%) 10/27/20 Early notable gainers among liquid option names on October 27th 10/16/20 Early notable gainers among liquid option names on October 16th
Initiation	United Bancorp Alabama initiated with a Buy at Janney Montgomery Scott » 07:08 01/19/21 01/19 07:08 01/19/21 07:08 UBAB United Bancorp Alabama $0.00 / + (+0.00%) Janney Montgomery Scott… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial

Hot Stocks	Scopus BioPharma completes clinical lot manufacturing » 07:08 01/19/21 01/19 07:08 01/19/21 07:08 SCPS Scopus BioPharma $13.30 / +0.29 (+2.23%) Scopus BioPharma… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Syndicate 16 Dec
Downgrade	H2O Innovation downgraded to Hold from Buy at Canaccord » 07:08 01/19/21 01/19 07:08 01/19/21 07:08 HEOFF H2O Innovation $0.00 / + (+0.00%) Canaccord Genuity analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings HEOFF H2O Innovation $0.00 / + (+0.00%) 12/16/20 H2O Innovation says Piedmont secure three FRP, coupling orders 12/08/20 H2O Innovation presents three-year strategic plan 12/01/20 H2O Innovation announces merger of three business lines 09/28/20 Utility Partners win operation, maintenance contract in Florida HEOFF H2O Innovation $0.00 / + (+0.00%) 12/11/20 Canaccord H2O Innovation price target raised to C$2.60 from C$2.50 at Canaccord 12/07/20 Canaccord H2O Innovation resumed with a Buy at Canaccord 09/25/20 Industrial Alliance H2O Innovation upgraded to Buy from Speculative Buy at Industrial Alliance 09/21/20 Desjardins H2O Innovation initiated with a Buy at Desjardins HEOFF H2O Innovation $0.00 / + (+0.00%) 09/24/20 H2O Innovation reports Q4 revenue C$35.98M vs. C$100M last year
Hot Stocks	Aclaris Therapeutics announces topline data from Phase 2a trial of ATI-450 » 07:07 01/19/21 01/19 07:07 01/19/21 07:07 ACRS Aclaris Therapeutics $5.88 / -0.2 (-3.29%) Aclaris Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Earnings ACRS Aclaris Therapeutics $5.88 / -0.2 (-3.29%) 11/04/20 Aclaris continues to pursue strategic alternatives, including seeking partners 11/04/20 Aclaris Therapeutics expects to submit investigational NDA for ATI-2138 in 2021 11/04/20 Aclaris Therapeutics files orphan drug designation for ATI-450-CAPS-201 11/04/20 Aclaris expects to report data from Phase 2a trial of ATI-450 in 1H21 ACRS Aclaris Therapeutics $5.88 / -0.2 (-3.29%) 11/04/20 Aclaris Therapeutics reports Q3 EPS (25c), consensus (30c) 08/07/20 Aclaris Therapeutics reports Q2 EPS (28c), consensus (36c)
Hot Stocks	Avrobio appoints Diana Escolar as CMO » 07:07 01/19/21 01/19 07:07 01/19/21 07:07 AVRO Avrobio $14.39 / -0.52 (-3.49%) , MGEN Miragen Therapeutics $23.29 / -1.8 (-7.17%) Avrobio (AVRO) announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events AVRO MGEN AVRO Avrobio $14.39 / -0.52 (-3.49%) 11/17/20 Avrobio announces new data in clinical programs 10/05/20 Avrobio to collaborate with University of Manchester for MPS II therapy 09/28/20 Avrobio gets orphan drug designation from the EC for AVR-RD-02 MGEN Miragen Therapeutics $23.29 / -1.8 (-7.17%) 12/17/20 Miragen Therapeutics enters license agreement with Xencor for Xtend technology 10/29/20 Point72 reports 9.5% passive stake in Miragen Therapeutics 10/28/20 Miragen Therapeutics acquires Viridian Therapeutics in stock-for-stock deal 10/05/20 Miragen Therapeutics falls 34% after resumption of trade to 50c per share AVRO MGEN AVRO Avrobio $14.39 / -0.52 (-3.49%) 11/18/20 Mizuho Avrobio price target raised to $43 from $35 at Mizuho 11/11/20 Berenberg Biotechnology companies initiated at Berenberg 11/11/20 Berenberg Avrobio initiated with a Buy at Berenberg 03/31/20 H.C. Wainwright Avrobio downgraded to Neutral from Buy at H.C. Wainwright MGEN Miragen Therapeutics $23.29 / -1.8 (-7.17%) 12/31/20 Oppenheimer Miragen Therapeutics price target raised to $37 from $5 at Oppenheimer 12/15/20 JMP Securities Miragen Therapeutics initiated with an Outperform at JMP Securities 11/24/20 Wedbush Miragen Therapeutics assumed with Outperform rating at Wedbush 10/06/20 Fly Intel: Top five analyst downgrades AVRO MGEN AVRO Avrobio $14.39 / -0.52 (-3.49%) 11/05/20 Avrobio reports Q3 EPS ($1.01), consensus (81c) 08/06/20 Avrobio reports Q2 EPS (80c), consensus (76c) MGEN Miragen Therapeutics $23.29 / -1.8 (-7.17%) 11/10/20 Miragen sees sufficient capital to fund through the end of 2023 11/10/20 Miragen Therapeutics reports Q3 EPS (10c), consensus (13c) 08/05/20 Miragen Therapeutics reports Q2 EPS (12c), consensus (16c) 20 Nov 13 Feb AVRO MGEN AVRO Avrobio $14.39 / -0.52 (-3.49%) 11/20/20 Fly Intel: Pre-market Movers 11/19/20 Fly Intel: After-Hours Movers MGEN Miragen Therapeutics $23.29 / -1.8 (-7.17%) 10/29/20 Fly Intel: After-Hours Movers 10/05/20 Fly Intel: After-Hours Movers 02/08/21 17th Annual Virtual WORLDSymposium 2021
Hot Stocks	Bausch + Lomb completes enrollment of first Phase 3 Study for NOV03 » 07:07 01/19/21 01/19 07:07 01/19/21 07:07 BHC Bausch Health $26.40 / -0.01 (-0.04%) Bausch + Lomb, a health… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options BHC Bausch Health $26.40 / -0.01 (-0.04%) 12/30/20 Bausch Health's DEXAVEN receives new indication in Poland 12/29/20 Bausch Health to reduce debt by $275M 11/24/20 Bausch Health begins second of Phase 3 studies of NOV03 11/16/20 Paulson & Co. buys Lear, cuts Tiffany in Q3 BHC Bausch Health $26.40 / -0.01 (-0.04%) 01/15/21 Jefferies Bausch Health price target raised to $33 from $27 at Jefferies 01/13/21 Truist Bausch Health CEO discussed inbound interest at conference, says Truist 11/05/20 Piper Sandler Bausch Health price target lowered to $25 from $26 at Piper Sandler 10/26/20 Barclays Bausch Health price target raised to $29 from $28 at Barclays BHC Bausch Health $26.40 / -0.01 (-0.04%) 01/12/21 Bausch Health sees Q4 revenue over $2.20B, consensus $2.12B 11/03/20 Bausch Health reports Q3 adjusted EBITDA $948M, consensus $844.9M 11/03/20 Bausch Health backs FY20 revenue view $7.8B-$8B, consensus $7.89B 11/02/20 Notable companies reporting before tomorrow's open BHC Bausch Health $26.40 / -0.01 (-0.04%) 12/29/20 Fly Intel: Pre-market Movers 10/08/20 Fly Intel: Pre-market Movers 08/06/20 Fly Intel: Pre-market Movers 07/27/20 Fly Intel: After-Hours Movers BHC Bausch Health $26.40 / -0.01 (-0.04%) 01/05/21 Bausch Health call volume above normal and directionally bullish 01/04/21 Bausch Health call volume above normal and directionally bullish 12/31/20 Largest borrow rate increases among liquid names 12/29/20 Bausch Health call volume above normal and directionally bullish

Initiation	First Reliance initiated with a Buy at Janney Montgomery Scott » 07:07 01/19/21 01/19 07:07 01/19/21 07:07 FSRL First Reliance $0.00 / + (+0.00%) Janney Montgomery Scott… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Hot Stocks	Proto Labs acquires 3D Hubs for $280M » 07:07 01/19/21 01/19 07:07 01/19/21 07:07 PRLB Proto Labs $168.63 / -6.51 (-3.72%) Proto Labs has entered… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings PRLB Proto Labs $168.63 / -6.51 (-3.72%) 07:07 Today Proto Labs acquires 3D Hubs for $280M 07:07 Today Proto Labs acquires 3D Hubs for $280M 07:06 Today Proto Labs acquires 3D Hubs for $280M 07:06 Today Proto Labs acquires 3D Hubs for $280M PRLB Proto Labs $168.63 / -6.51 (-3.72%) 10/20/20 Northcoast Prototyping business survey shows COVID ongoing drag, says Northcoast 10/09/20 Berenberg Proto Labs assumed with a Hold at Berenberg 05/14/20 Benchmark Benchmark starts Proto Labs at Buy, sees COVID-19 programs filling order gap 05/14/20 Benchmark Proto Labs initiated with a Buy at Benchmark PRLB Proto Labs $168.63 / -6.51 (-3.72%) 10/29/20 Proto Labs sees Q4 revenue $96M-$106M, consensus $107.3M 10/29/20 Proto Labs reports Q3 non-GAAP EPS 67c, consensus 52c 07/28/20 Proto Labs sees Q3 revenue $98M-$110M, consensus $103.95M 07/28/20 Proto Labs reports Q2non-GAAP EPS 59c, consensus 36c
Hot Stocks	Proto Labs acquires 3D Hubs for $280M » 07:07 01/19/21 01/19 07:07 01/19/21 07:07 PRLB Proto Labs $168.63 / -6.51 (-3.72%) Proto Labs has entered… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings PRLB Proto Labs $168.63 / -6.51 (-3.72%) 07:07 Today Proto Labs acquires 3D Hubs for $280M 07:06 Today Proto Labs acquires 3D Hubs for $280M 07:06 Today Proto Labs acquires 3D Hubs for $280M 12/14/20 Proto Labs announces Robert Bodor to succeed Vicki Holt as CEO PRLB Proto Labs $168.63 / -6.51 (-3.72%) 10/20/20 Northcoast Prototyping business survey shows COVID ongoing drag, says Northcoast 10/09/20 Berenberg Proto Labs assumed with a Hold at Berenberg 05/14/20 Benchmark Benchmark starts Proto Labs at Buy, sees COVID-19 programs filling order gap 05/14/20 Benchmark Proto Labs initiated with a Buy at Benchmark PRLB Proto Labs $168.63 / -6.51 (-3.72%) 10/29/20 Proto Labs sees Q4 revenue $96M-$106M, consensus $107.3M 10/29/20 Proto Labs reports Q3 non-GAAP EPS 67c, consensus 52c 07/28/20 Proto Labs sees Q3 revenue $98M-$110M, consensus $103.95M 07/28/20 Proto Labs reports Q2non-GAAP EPS 59c, consensus 36c
Hot Stocks	Proto Labs acquires 3D Hubs for $280M » 07:07 01/19/21 01/19 07:07 01/19/21 07:07 PRLB Proto Labs $168.63 / -6.51 (-3.72%) Proto Labs has entered… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings PRLB Proto Labs $168.63 / -6.51 (-3.72%) 07:06 Today Proto Labs acquires 3D Hubs for $280M 07:06 Today Proto Labs acquires 3D Hubs for $280M 12/14/20 Proto Labs announces Robert Bodor to succeed Vicki Holt as CEO PRLB Proto Labs $168.63 / -6.51 (-3.72%) 10/20/20 Northcoast Prototyping business survey shows COVID ongoing drag, says Northcoast 10/09/20 Berenberg Proto Labs assumed with a Hold at Berenberg 05/14/20 Benchmark Benchmark starts Proto Labs at Buy, sees COVID-19 programs filling order gap 05/14/20 Benchmark Proto Labs initiated with a Buy at Benchmark PRLB Proto Labs $168.63 / -6.51 (-3.72%) 10/29/20 Proto Labs sees Q4 revenue $96M-$106M, consensus $107.3M 10/29/20 Proto Labs reports Q3 non-GAAP EPS 67c, consensus 52c 07/28/20 Proto Labs sees Q3 revenue $98M-$110M, consensus $103.95M 07/28/20 Proto Labs reports Q2non-GAAP EPS 59c, consensus 36c
Recommendations	Arcus Biosciences price target raised to $70 from $45 at Truist » 07:07 01/19/21 01/19 07:07 01/19/21 07:07 RCUS Arcus Biosciences $37.00 / -1.715 (-4.43%) Truist analyst Robyn… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events RCUS Arcus Biosciences $37.00 / -1.715 (-4.43%) 01/15/21 Arcus Biosciences presents preliminary data from ARC-8 study 12/09/20 Arcus Biosciences expands partnership with WuXi on anti-CD39 antibodies 11/13/20 Surface announces SRF617, SRF388 to advance to combination, expansion stages 10/29/20 Arcus Biosciences to collaborate with AstraZeneca on trial for domvanalimab RCUS Arcus Biosciences $37.00 / -1.715 (-4.43%) 01/13/21 Cantor Fitzgerald Arcus Biosciences price target raised to $62 from $39 at Cantor Fitzgerald 12/22/20 Mizuho Autolus, Arcus among top 2021 oncology picks at Mizuho 11/24/20 Berenberg Arcus Biosciences initiated with a Buy at Berenberg 11/23/20 Evercore ISI Arcus Biosciences initiated with an Outperform at Evercore ISI RCUS Arcus Biosciences $37.00 / -1.715 (-4.43%) 11/05/20 Arcus Biosciences reports Q3 EPS 3c, consensus 5c 08/06/20 Arcus Biosciences reports Q2 EPS (93c), consensus (61c) 29 May 01/20/21 Arcus Biosciences

Events

Earnings calls, analyst events, roadshows and more

CMA
Today at 08:00

Comerica - CMA Conference Calls
PETS
Today at 08:00

PetMed Express - PETS Conference Calls
BAC
Today at 08:30

Bank of America - BAC Conference Calls
LOGI
Today at 08:30

Logitech - LOGI Conference Calls
HAL
Today at 09:00

Halliburton - HAL Conference Calls
EPAC
Today at 09:00

Enerpac Tool Group Corp Firm Sponsored Meetings

N86 W12500 Westbrook Crossing, Menomonee Falls, WI
OACB
Today at 09:00

OAKTREE ACQUISITION CORP. II Firm Sponsored Meetings

New York, NY
Today at 09:00

Healthcare Industry Meetings
GS
Today at 09:30

Goldman Sachs - GS Conference Calls
Today at 10:00

Board of Directors Meeting Government Event

Virtual Meeting

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	DFH X DFH Dream Finders Homes IPO Managers: BofA, RBC Capital & BTIG, Builder Advisor, Zelman, TCB Capital, Wedbush $12.00-15.00 9.6M Shares MYTE X MYTE Mytheresa IPO Managers: Morgan Stanley & JPMorgan, Credit Suisse, UBS, Jefferies, Cowen $16.00-18.00 15.647M Shares
Thurs	PAX X PAX Patria IPO Managers: JPMorgan, BofA & Credit Suisse, Goldman Sachs, Bradesco BBI, BTG Pactual, ITAU, Keefe Bruyette, Santander, XP $14.00-16.00 26.65M Shares
Fri	No deals

View All Syndicate Announcements »

Bristol-Myers announces approval of Opdivo in Europe

TODAY'S FREE FLY STORIES

Get Full Fly Access